Buradasınız

Anasayfa » Content

FEBRİL NÖTROPENİK HASTALARDA SERUM İNTERLÖKİN-6 DÜZEYLERİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Serum interleukin-6 levels in febrile neutropenic patients. Infectious complications represent a significant cause of mortality in thc patients with chemotherapy-induced neutropenia. Management of these patients ineludes hospitalİzatİon and administration of broad-speetrum antibiotics. This study prospectiveîy evaluates that serum interleukin-6 level (IL-6) is predictor of fever due to infecfion in the patients with chemotherapy-induced neutropenia and that IL-6 is marker of disease severity. Serum IL-6 levels, measured by ELISA, were assessed in 26 patients with hematological malignaney for 31 episodes of chemotherapy-induced neutropenia. Twenty-sİx of these episodes wcrc febrile neutropenic attacks. Fourteen of febrile neutropenic episodes were classified as severe and life threatening, but 12 as mild and moderate attacks. IL-6 levels were significantiy higher within 24 hours after onset of fever in the patients with severe and life-threatening course than in those with mİId and moderate course (respectively, 162.71+172.43 pg/ml, 28.04+14.96 pg/ml, p<0.00001). Two patients who have the highest I L - 6 levels have died during those episodes. Between these two groups of patients, serum IL-6 levels measured before and after febrile neutropenic episodes showed no significantiy differences. There were positive correlations of IL-6 with CRP, and also of IL-6 with presence of fever. These results show usefulness of serum I L - levels as indicator of severe infectİons İn febrile neutropenic patients
Bookmark/Search this post with
Abstract (Original Language): 
Kemoterapi sonrası nötropeni gelişen hastalarda ortaya çıkan infcksİyonlar önemli bir mortalite nedenidir. Bu hastaların hastaneye yatırılması ve geniş spektrumlu antibiyotiklerle yoğun tedavi uygulanması gerekir. Bu çalışmada prospektif olarak, kemoterapiye bağlı nötropeni gelişen hastalarda interlökin-6 (IL-6) düzeylerinin hastalarda İnfeksİyona bağlı ateş yükselmesinin bir prediktörü olup olmadığı, febril nötropenik ataklarda IL-6 düzeylerinin prognostik gösterge olup olmadığı araştırıldı. Çalışmada hematolojik maiign hastalık nedeniyle kemoterapi uygulanan 26 hastadaki, 31 nötropeni atağı izlendi. Febril nötropeni gelişen 26 atağın 14'ü ağır, 12'si hafif olarak değerlendirildi. Serum IL-6 düzeyleri ELISA yöntemi İle tayin edildi. Ciddi ve hayatı tehdit eden febril nötropenik ataklarda, ateş yükseldikten sonraki ilk 24 saat içinde tayin edilen IL-6 düzeyleri, tablonun hafif seyrettiği hastalardan yüksek bulundu (sırası ile 162.71+172.43 pg/ml, 28.04±14.96 pg/ml, p<0.00001). En yüksek IL-6 düzeyi bulunan 2 hasta bu atak sırasında kaybedildi. Hafif ve ağır seyir gösteren hasta gruplarında, ateş yükselmeden önce ve atak sonlandıktan sonra bakılan IL-6 düzeyleri arasında fark bulunmadı. IL-6 İle CRP düzeyleri ve ateş süresi arasında anlamlı, pozitif korelasyon bulundu . IL-6 düzeyinin 40 pg/dİ'den yüksek olması "cutoff" değeri olarak alındığında, IL-6 düzeyleri febril nötropenik hastalarda, ciddi risk taşıyan olguları gösteren değerli bir gösterge gibi gözükmektedir
FULL TEXT (PDF): 
PDF icon arastirmax-febril-notropenik-hastalarda-serum-interlokin-6-duzeyleri.pdf
  • 3
246-250
  • Turkish

REFERENCES

References: 

1. De Bont ESJM, Vellenga E, Sv/aanenburg JCJM, Fidler V, VİsseT-Vun Brummen PJ, Kamps WA; Piosma IL-8 ;ınd IL-6 levels can bc used to define a group with Iow risk of septicemia among cancer patienfs with fever and neutropenia. Br J Hematol 107: 375 (1999).
2. Engel A, Mack E, Kern P, Keın WV: An analysis of in-tcrleukin-8, interleukin-6 and C-reactivc proieili serum concenlratioııs to predict fever, gram-negalive bacterc-ınia and complicated infection in neutropenic cancer patients. Infection 26:213(1998).
3. Gozzard DI, Frendi EA, Blccher TE, POwell RJ: C-rcac-tive protein levels in neutropenic patients with pyrexia. Clin Lab Haematol 7: 307 (1985).
4. Hack CE, de Groot ER, Fclt-Bersma RJF, Nuyens JF, Strack van Schijndel RJM, Eerenberg-Belmer AJM, Tfıijs LG, Aarden LA: Increascd pSasıııa levels of interlc-ukin-6 levels in sepsis. Blood 74: 1704(1989).
5. Heney D, Lewis IJ, Evans SW, Banks R, Bailey CC, Whicher JT: Inteıieukin-6 and ils relalionship to C-reac-tive protein and fever in children with febrile neutropenia. J Infect Dis 165: 886 (1992).
6. Hughes WT, Armstrong D, Bodey GP, Brown AE, Ed-waıds JE, Felci R, Pizzo P, Rolslon KVI, Shenep JL, Yo-ung LS: From Ihe Infectious Dİseasc Society of America: guidelines for the use of antimierobiai agents in neutropenic patients with unexplained fever. Clinic Infect Dis 25:55i (İ997).
7. Lcc J.W, Pizzo PA: Management of cancer patient with fever and prolonged neutropeniü. Hematol Oncol Clin N Am7: 937(1993).
8. Lehrnbecher Ttı. Venzon D, de Haas M, Chanock SJ, Kühl J: Assesment of measuring circtılating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc( receptor type 113, and mannose-binding protein in febrile children wifh cancer and neutropenia. Clin Infect Dis 29: 414(1999).
9. Ostermann H, Rothenburger M, Mesters RM, van de Loo .1, Kienast J: Cytokine response lo infection in patients with acute myeiogenous leukemia foliowing intensive ehemotherapy. Br J Haematol 88: 332 (1994).
10. Pizzo AP: Management of fever in patients with cancer and treatment-induccd neutopenia. N Eng J Mcd 328: 1323 (1993).
11. Steinmetz HT, Herbertz A, Bertram M, Diehl V: Increase in interleukin-6 serum level preceding fever in granu-locytopeııia and coırelation with death from sepsis. J Infect Dis 171:225 (1995).
12. Van Snick J: Intcrleukin-6: An overview. Annu Rev Im-münöl. 8:253 (1990).
13. Waage A, Steinsham S: Cytokine mediators of septic in-feetions in normal and granulocytopenic host. Eur J Hae-mato 50; 243(1993).
14. VVilliams M, MeCallum J, Dick HM: The deteetion of infection in leukemia by serial measurement of C-reactive protein. J Infect 4: 139 (1982).
15. VVolvckamp MCJ, Marquet RL: InterIeukin-6: hİstorical backgroıtntl, genetİcs and biological significancc. Inımu-ııol Letters.24: 1 (1990).
250

Thank you for copying data from http://www.arastirmax.com